Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

New England Journal of Medicine

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL